Osteoporosis

 

How COVID-19 Has Altered Assessment and Treatment of Osteoporosis

February 15, 2021

A study published in Osteoporosis International focused on the changes that have occurred over the course of the pandemic for patients with osteoporosis and found that there have been delays in dual-energy X-ray absorptiometry (DXA) scanning, problems with medication supply, a decrease in face-to-face consultations, and reductions in parenteral medication delivery.

Zoledronic Acid Associated With Higher Risk for Atrial Fibrillation Than Denosumab

January 22, 2021

“Based on 16,235 pairs of zoledronic acid and denosumab initiators (for osteoporosis), we found a greater risk (HR 1.25, 95% CI 1.04-1.50) of atrial fibrillation with zoledronic acid vs denosumab: an absolute risk difference of 3.69 events per 1000 person-years,” said Seoyoung Kim, MD, ScD.

Bisphosphonates Show No Significant Benefit for Hip Fracture Risk after Five Years

January 19, 2021

Dr Joan Lo, MD, a research scientist with the Kaiser Permanente Northern California Division of Research, said: “We found that hip fracture risk in women did not differ if women stopped bisphosphonate use after five years or stayed on the medication for 10 years. Whether there is a benefit to staying on the drug for seven years needs to be further studied in randomized trials.”

Study Highlights Osteoporosis Risk in Gay Men

December 10, 2020

Non-heterosexual minority men have a greater risk of poor bone health than heterosexual men, and this risk appears to be independent of lifestyle and psychosocial factors, suggests a study published in the American Journal of Human Biology.